Literature DB >> 24061523

Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses.

Michael T Tetzlaff1, Wei-Lien Wang, Tiffani L Milless, Jonathan L Curry, Carlos A Torres-Cabala, Michael S McLemore, Doina Ivan, Roland L Bassett, Victor G Prieto.   

Abstract

The diagnosis of benign versus malignant melanocytic proliferations remains an important challenge. The current diagnostic algorithm typically involves an assessment of histopathologic and immunohistochemical parameters by light microscopy. Recently, fluorescence in situ hybridization (FISH) was reported as a useful ancillary diagnostic tool in melanocytic lesions, but the utility of FISH in melanocytic tumors that are difficult to diagnose with standard morphologic analysis remains controversial. To address this issue, we collected 34 ambiguous melanocytic tumors for FISH testing (NeoGenomics). Before FISH testing, cases were designated as "favor benign" (n=24) or "favor malignant" (n=10) by a consensus group (up to 7 dermatopathologists) on the basis of clinical, histopathologic, and immunophenotypic parameters. FISH was positive in 3/24 "favor benign" lesions and in 5/10 "favor malignant" lesions. The histopathologic, immunophenotypic, and FISH parameters informing our diagnostic impression were correlated with the final consensus diagnosis and clinical follow-up; in all cases, the initial diagnosis remained unchanged. In this series, the sensitivity of FISH for the histopathologic diagnosis of melanoma was 50%, the specificity was 87.5%, the positive predictive value was 62.5%, and the negative predictive value was 80.7%. Follow-up information was available for 25 patients (17 benign and 8 malignant diagnoses). Among benign lesions, the mean follow-up was 16.8 months (range, 8 to 25 mo); no metastases have been reported to date. Among the malignant lesions, the mean follow-up was 14.6 months (range, 7 to 23 mo); a single lymph node metastasis was identified in a 4-year-old girl with a histopathologic diagnosis of melanoma, which was negative on FISH. In our experience, in the setting of a lesion with predominantly benign findings, a negative FISH test-given its high specificity-is a reassuring finding that supports a benign diagnosis. In contrast, a positive FISH test should be carefully interrogated in the context of the complete histopathologic findings.

Entities:  

Mesh:

Year:  2013        PMID: 24061523     DOI: 10.1097/PAS.0b013e31829d20f5

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions.

Authors:  Eugen C Minca; Rami N Al-Rohil; Min Wang; Paul W Harms; Jennifer S Ko; Angela M Collie; Ivanka Kovalyshyn; Victor G Prieto; Michael T Tetzlaff; Steven D Billings; Aleodor A Andea
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

Review 2.  Review of diagnostic, prognostic, and predictive biomarkers in melanoma.

Authors:  Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 3.  Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis.

Authors:  Jayson Miedema; Aleodor A Andea
Journal:  Mod Pathol       Date:  2020-02-17       Impact factor: 7.842

Review 4.  Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I.

Authors:  Luiz Guilherme Martins Castro; Maria Cristina Messina; Walter Loureiro; Ricardo Silvestre Macarenco; João Pedreira Duprat Neto; Thais Helena Bello Di Giacomo; Flávia Vasques Bittencourt; Renato Marchiori Bakos; Sérgio Schrader Serpa; Hamilton Ometto Stolf; Gabriel Gontijo
Journal:  An Bras Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.896

Review 5.  Emerging clinical applications of selected biomarkers in melanoma.

Authors:  Michael T Tetzlaff; Carlos A Torres-Cabala; Penvadee Pattanaprichakul; Ronald P Rapini; Victor G Prieto; Jonathan L Curry
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.